Introduction
The metastatic spread of tumor cells is the most lethal aspect of cancer. Similar to angiogenesis, lymphangio-genesis is the formation of lymphatic vessels, during which lymphatic endothelial cells (LECs) sprout to form new vessels from preexisting lymphatic vessels. Lymphangiogenesis has important roles in tissue homeostasis, metabolism and immunity. Lymphatic vessel formation also contributes to pathological conditions such as tumor invasion to lymph nodes and metastasis (Alitalo et al., 2005) . The role of the lymphatic network in human diseases has received renewed interest largely due to the identification of specific signaling pathways that regulate the formation of lymphatic systems, which are vascular endothelial growth factor-C (VEGF-C) and its cognate receptor VEGF receptor-3 (VEGFR3). VEGF-C stimulates tumor lymphangiogenesis and metastasis by interacting with VEGFR3 (Alitalo et al., 2005) .
VEGF was known to regulate angiogenesis in a paracrine manner, in which VEGF produced by nonendothelial cells in surrounding tissues binds to its cognate receptors on endothelial cells to activate the angiogenic signaling pathway. However, it was recently found that abrogation of endogenous VEGF production in endothelial cells leads to apoptosis and thrombosis. And interestingly, addition of endogenous, but not exogenous, VEGF rescued the phenotype (Helotera and Alitalo, 2007; Lee et al., 2007) . As endogenous and exogenous VEGF function through the same receptor, VEGFR2, on endothelial cells, these findings imply that autocrine and paracrine signaling events by VEGF in endothelial cells possess different and non-overlapping functions. Currently, it is unclear whether VEGF-C possesses a similar cell-autonomous signaling role in LECs.
Hypoxia is commonly associated with many tumors. The transcription factor hypoxia-inducible factor-1 (HIF-1) is a major regulator of tissue response to hypoxia (Semenza, 1998) . HIF-1 regulates tumor progression by upregulating its target genes, including genes associated with angiogenesis and lymphangiogenesis (Katsuta et al., 2005) . Hypoxia promotes lymphangiogenesis in human breast cancer and lung carcinoma (Schoppmann et al., 2006; Simiantonaki et al., 2008) . In various types of cancer, HIF-1a expression is positively correlated with lymphatic metastasis (Kurokawa et al., 2003; Kuwai et al., 2003) .
CCAAT/enhancer-binding protein-d (C/EBP-d) is a transcription factor that belongs to the C/EBP family. It is strongly induced by inflammatory cytokines, and has a role in inflammation (Poli, 1998; Rabek et al., 1998; Takata et al., 2002) . The level of C/EBP-d in carcinoma is elevated compared with that in the surrounding normal tissue (Kim and Fischer, 1998; Milde-Langosch et al., 2003) , indicating a positive role of the gene in tumorigenesis. However, the underlying molecular mechanism remains unclear. One major function of C/EBP-d is regulation of gene expression, such as expression of proapoptotic genes, during mammary gland involution (Thangaraju et al., 2005) , and plateletderived growth factor receptor expression that affects smooth-muscle-cell proliferation (Kitami et al., 1999; Yang et al., 2001) . In addition, C/EBP-d expression is elevated under hypoxic conditions in both neonatal and adult brains (Tang et al., 2006) .
In this study, we show a previously unknown function of C/EBP-d in promoting lymphangiogenesis and lung metastasis through regulation of VEGFR3 signaling in LECs. We show that C/EBP-d is expressed in LECs and regulates lymphatic angiogenic gene expression through HIF-1a. Genetic deletion of C/EBP-d impairs lymphangiogenesis and metastasis. Thus this study links hypoxia to VEGF-C signaling in lymphangiogenesis and metastasis through C/EBP-d.
Results
Genetic deletion of C/EBP-d in mice resulted in a reduction of lymphangiogenesis and pulmonary metastasis of lung cancer C/EBP-d is strongly induced by inflammatory cytokines (Rabek et al., 1998; Takata et al., 2002) , and the levels of C/EBP-d in carcinoma are significantly higher than that in surrounding normal tissues (Kim and Fischer, 1998; Milde-Langosch et al., 2003) , suggesting a positive role of the gene in tumorigenesis. To test this hypothesis, we used C/EBP-d-null mice. Mice without the C/EBP-d gene are viable, grossly normal and fertile except subtle defects in adipocyte differentiation, mammary gland involution, and specific types of learning and memory (Tanaka et al., 1997; Sterneck et al., 1998; Johnson, 2005) . We injected 3LL tumor cells into the C/EBP-d-null mice and wild-type mice through the tail vein, followed by assaying lung colonization of tumor cells, a commonly used model for vascular metastasis. Interestingly, there was a significant reduction of tumor metastasis as measured by counting lung surface metastases and lung weight in C/EBP-delta null mice compare to controls .
As lymphatic networks are critical for metastasis, we therefore examined the effects of C/EBP-d inactivation on lymphangiogenesis. Immunohistological staining of pulmonary metastases sections showed fewer Lyve-1positive lymphatic vessels in tumors from the C/EBP-dnull mice than that in tumors from wild-type mice (Figures 1d and e ). These findings support a positive role of C/EBP-d in tumor malignancy through regulation of lymphangiogenesis. It suggests that defective tumor lymphangiogenesis associated with C/EBP-d inactivation contributes to reduced tumor metastasis.
C/EBP-d specifically regulates VEGF-C and VEGFR3 expression in LECs
As C/EBP-d is known to regulate gene expression, we examined the potential role of C/EBP-d in lymphangiogenic gene expression by comparing tissues isolated from wild-type and null mice. We did not see any differences in VEGF-C expression in tumors between the two groups (Figure 2a ), nor did we see any difference in VEGF-C expression in the bone marrow between the null and wild-type mice (Figure 2b) . Surprisingly, an analysis of VEGF-C expression in freshly isolated murine pulmonary lung LECs (pooled from five mice in each group) showed a dramatic reduction of VEGF-C in C/EBP-d-null cells compared with that in wild-type cells (Figures 2c and d) . Similarly, there is a clear reduction of VEGFR3 in the C/EBP-d-null LECs (Figures 2c and d) . Moreover, forced expression of C/EBP-d in primary human LECs promoted VEGF-C and VEGFR3 expression in these cells (Figure 2e ). These findings point to a specific role of C/EBP-d in In addition, VEGFR3 signaling is known to provide a survival signal for LECs (Makinen et al., 2001) , and there seemed to be more apoptotic cells with C/EBP-d knockdown in LECs present in the vascular network formation assay ( Figure 3g ). Therefore, we examined the effects of C/EBP-d on LEC survival using flow cytometry. We found that knockdown of C/EBP-d in human LECs using specific shRNA constructs significantly increased apoptosis as measured by propidium iodide and Annexin-V staining when compared with control vector-transfected cells (Figures 4a and c) , confirming a function of C/EBP-d in lymphatic endothelial survival. As VEGF-C confers a survival signal in the lymphatic endothelium (Makinen et al., 2001) and C/EBP-d regulates VEGF-C expression in LECs, we attempted to rescue the phenotype with the addition of recombinant VEGF-C protein. Surprisingly, the recombinant protein increased cell survival only slightly and it did not reach statistical significance when compared with that in C/EBP-d-knockdown cells (Figures 4b and c ).
Deletion of endogenous VEGF production in endothelial cells leads to apoptosis, which cannot be compensated for by exogenous VEGF, even though endogenous and exogenous VEGF both function through the same receptor, VEGFR2 (Helotera and Alitalo, 2007; Lee et al., 2007) . These findings imply that VEGF autocrine signaling does not fully overlap with paracrine signaling. Thus, we reasoned a similar mechanism of VEGF-C autocrine signaling in LEC survival, as deletion of C/EBP-d resulted in a lymphatic endothelium-specific reduction of VEGF-C (Figures 2c  and d) . To test the hypothesis, we transfected cells with a VEGF-C expression vector in C/EBP-d-knockdown LECs, followed by analysis of cell survival. Interestingly, forced expression of VEGF-C in LECs totally rescued the phenotype (Figures 4b and c ). Taken together, these findings support that C/EBP-d regulates cell-autonomous VEGF-C autocrine signaling in the lymphatic endothelium, which cannot be compensated for by paracrine VEGF-C signaling.
C/EBP-d regulates VEGF-C and VEGFR3 expression in LECs through HIF-1a
To further dissect the gene regulation mechanism, we first determined the potential effects of C/EBP-d on the HIF-1 transcription factor as it functions as a key regulator in angiogenic gene expression. We found that deletion of C/EBP-d in murine pulmonary LECs resulted in a significant reduction of HIF-1a levels when compared with that in cells isolated from wild-type mice ( Figure 5a ). Interestingly, exposure of cultured human LECs to hypoxic conditions induced the expression of C/EBP-d ( Figure 5b ). Thus, the results point to a positive feedback regulation of HIF-1a in hypoxia through C/EBP-d in the lymphatic endothelium. Consistently, forced expression of C/EBP-d in LECs increased the production of VEGF-C and VEGFR3 under both normoxic and hypoxic conditions, with more pronounced gene induction under hypoxia (Figure 5c ). Conversely, knockdown of C/EBP-d inhibited the production of VEGF-C and VEGFR3 under normoxic conditions. More importantly, it totally blocked the hypoxia-induced production of VEGF-C and VEGFR3 in LECs (Figure 5d ), illustrating a key role of C/EBP-d in lymphangiogenic gene expression under hypoxia. As HIF-1 is a master regulator of angiogenic gene expression under hypoxia, we next examined whether HIF-1 is responsible for C/EBP-d-mediated gene expression in LECs by using an HIF-1a-specific inhibitor. We found that neutralization of HIF-1a activity significantly blocked C/EBP-d-induced VEGF-C and VEGFR3 production ( Figure 5e ). It also reduced the basal levels of C/EBP-d in these cells, consistent with the observation that hypoxia upregulates the production of C/EBP-d (Figure 5e ). Collectively, these data suggest that C/EBP-d regulates VEGF-C and VEGFR3 expression through the HIF-1 transcription factor.
Discussion
Cancer metastasis is a hallmark of malignancy, contributing to about 90% of human cancer deaths. The lymphatic Role of C/EBP-d in lymphangiogenesis Y Min et al system is important for the metastatic spread of cancer. Therefore, understanding the underlying molecular mechanisms of lymphangiogenesis is highly important. In this study, we report a specific and significant function of C/EBP-d in regulating VEGF-C/VEGFR3 signaling in the lymphatic endothelium. C/EBP-d is expressed in LECs. It regulates the production of VEGF-C and VEGFR3 in lymphangiogenesis and tumor metastasis. Interestingly, forced expression of VEGF-C, but not recombinant VEGF-C, rescued the inactivation of C/EBP-d-induced cell apoptosis, indicating cell-autonomous VEGF-C signaling in lymphatic endothelial survival. Further analysis shows that hypoxia induces C/EBP-d expression and deletion of C/EBP-d inhibited HIF-1a transcription, suggesting a positive feedback regulation of hypoxia response in LECs ( Figure 6 ). Interestingly, blocking HIF-1a activity totally blocked CEBP-d-induced VEGF-C and VEGFR3 expression in LECs. These findings link hypoxia to lymphangiogenesis through C/EBP-d and VEGF-C autocrine signaling ( Figure 6 ). Role of C/EBP-d in lymphangiogenesis Y Min et al C/EBP-d belongs to the C/EBP transcription family, and is present in a variety of cells at very low levels in normal situations. However, it is rapidly induced by a variety of stimuli, such as inflammatory cytokines (Ramji and Foka, 2002) . As inflammation is directly linked to tumor initiation and progression, it is no surprise that C/EBP-d levels are significantly higher in carcinomas than in surrounding normal tissues (Kim and Fischer, 1998; Milde-Langosch et al., 2003) , indicating a positive role of C/EBP-d in tumor development. In the present study, we found that inactivation of C/EBP-d in mice led to a significant reduction of VEGF-C/VEGFR3 signaling in the lymphatic endothelium and pulmonary metastasis. These findings provide a molecular mechanism supporting a positive role of C/EBP-d in tumor progression through regulation of lymphatic angiogenic gene expression and lymphangiogenesis.
Clinical and preclinical findings have long suggested tumor-associated lymphatics as a key component of tumor metastasis (Stacker et al., 2002) . Lymphangiogenesis has traditionally been overshadowed by angiogenesis owing to a lack of lymphangiogenic factors, as well as suitable markers to distinguish blood from the lymphatic vascular endothelium. However, the field has advanced rapidly after the identification of VEGF-C and VEGFR3 signaling in lymphangiogenesis (Alitalo and Carmeliet, 2002) . VEGF-C À/À embryos lack lymphatic vessels and die prenatally because of severe tissue edema (Karkkainen et al., 2004) , whereas VEGFR3 À/À mice die from defective vascular remodeling before establishment of lymphatic vessels (Dumont et al., 1998) . The degree of tumor lymphangiogenesis and VEGF-C and VEGFR3 levels are highly correlated with the extent of lung metastasis (Yonemura et al., 1999; Akagi et al., 2000; Alitalo and Carmeliet, 2002) . Overexpression of VEGF-C increases tumor metastasis (Skobe et al., 2001) , and conversely, blocking VEGFR3 function neutralizes metastasis (He et al., 2002) . Despite the importance of VEGFR3 signaling in lymphangiogenesis, the transcriptional machinery regulating lymphangiogenic gene expression is not very clear. The current study identifies C/EBP-d as a transcription factor important for the production of VEGF-C and VEGFR3 in the lymphatic endothelium. We show that C/EBP-d is expressed in LECs, and deletion or knock- VEGF was thought to function in a paracrine manner to regulate angiogenesis. Surprisingly, genetic deletion of endogenous VEGF production in vascular endothelial cells leads to apoptosis, despite that total levels of VEGF are not detectably altered (Helotera and Alitalo, 2007; Lee et al., 2007) . This indicates a nonoverlapping, cell-autonomous and essential function of VEGF autocrine signaling in vascular endothelial survival and homeostasis. Interestingly, we found that loss of C/EBP-d dramatically reduced the levels of VEGF-C in LECs, without detectable changes of VEGF-C levels in tumor tissues and bone marrow cells, implying a specific role of C/EBP-d in the regulation of endogenous VEGF-C expression in LECs. Importantly, recombinant VEGF-C failed to rescue the phenotype associated with C/EBP-d inactivation in LECs, but forced expression of VEGF-C totally rescued the defective phenotype. Thus, our data show that VEGF-C possesses a similar cellautonomous autocrine signaling mechanism in LEC survival as VEGF does in vascular endothelial homeostasis. C/EBP-d regulates this activity through regulation of VEGF-C expression specifically in LECs. Current effort is targeted at understanding the cell type-specific gene regulation mechanism manifested by C/EBP-d.
Hypoxia is a common feature of tumors, and acts as a potent regulator of angiogenesis through activation of the HIF transcription factor. Findings also report a similar function of hypoxia in modulating lymphangiogenesis (Irigoyen et al., 2007; Ota et al., 2007) . HIF-1a promotes lymphatic metastasis through regulation of VEGF-C in human cancer (Katsuta et al., 2005) . Here, we show that C/EBP-d is upregulated under hypoxia, and inactivation of C/EBP-d reduced HIF-1a levels in LECs. In addition, neutralization of HIF-1a activity totally blocked the C/ EBP-d-mediated expression of VEGF-C and VEGFR3 in LECs. This observation corresponds with the finding that hypoxia-driven VEGF autocrine signaling is perturbed by a deficiency in endothelial cell HIF-1a (Tang et al., 2004) . In addition, we also examined the expression of HIF-2 as this transcription factor also regulates VEGF expression and angiogenesis. We found that overexpression of C/EBP-d in LECs has no effects on HIF-2a expression under normoxia and hypoxia (data not shown), suggesting that HIF-2 is unlikely to have a role in the gene regulation. Based on these findings, we suggest that hypoxia stabilizes the basal levels of HIF-1a that activate C/EBP-d transcription. In return, C/EBP-d induces HIF-1a transcription, which regulates lymphangiogenic gene transcription, thereby forming a positive feedback regulation mechanism.
In summary, this study shows that C/EBP-d, a transcription factor, regulates VEGF-C autocrine signaling in LECs. Consistent with the hypothesis that autocrine signaling is triggered by stress, we show that hypoxia upregulates the expression of C/EBP-d, thereby forming a positive feedback regulation mechanism that propagates angiogenic signals in the lymphatic endothelium. These data provide molecular evidence linking C/ EBP-d to lymphangiogenesis and tumor metastasis. Thus, C/EBP-d is an appealing target for tumor therapy, providing a means to control VEGFR3 signaling in lymphangiogenesis.
Materials and methods
Mice and cell lines C57BL/6J mice from Jackson Labs (Bar Harbor, ME, USA) and C/EBP-d-null mice in the C57BL/6 background from the NCI (Sterneck et al., 1998) were housed in a pathogen-free unit at the Vanderbilt University School of Medicine in compliance with the Institution of Animal Care and Use Committee (IACUC) regulations. Six-week-old female mice were injected with 1 Â 10 5 3LL cells in 100 ml of phosphate-buffered saline through the tail vein. Fourteen days after inoculation, lungs were excised and the number of pulmonary tumor colonies was counted, and the lungs were weighed. Human lung LECs (HMVEC-LLy) were purchased from Lonza (Walkersville Inc., Walkersville, MD, USA), and cultured according to the manufacturer's protocol. All experiments were performed on cells between 3 and 7 passages. Lewis lung adenocarcinoma cells (3LL) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% serum.
Immunohistochemistry
Tumors were harvested, processed and paraffin tissue sections were stained with an antibody against Lyve-1 (MBL, Woburn, MA, USA), and counterstained with hematoxylin. The number of Lyve-1-positive lymphatic vessels was counted in 10 randomly selected Â 200 fields under a microscope.
Isolation of pulmonary LECs
Age-and sex-matched wild-type and C/EBP-d-null mice were killed. Single-cell suspension was prepared from lungs as described (Kamiyama et al., 2006) . The cell suspension was incubated with the Lyve-1-PE antibody from MBL. Positive cells were sorted using a FACStarPlus flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Cell purity was confirmed by immunostaining with an Lyve-1 antibody. The cells used in each study were greater than 95% pure.
Expression and knockdown of C/EBP-d HMVEC-LLy cells were transfected using the Nucleofector kit (Lonza, VPB-1002). Twenty-four hours after transfection, the cells were treated under normoxic or hypoxic conditions for 48 h followed by analysis of gene expression. For overexpression, the cells were transfected with a PCDNA 3.1-C/ EBP-d plasmid or an empty vector as control. For knockdown, an shRNA plasmid DNA specific for C/EBP-d and a nonspecific shRNA plasmid obtained from Sigma-Aldrich (St Louis, MO, USA) were used. Puromycin at 0.5 mg/ml was used for enrichment of shRNA-transfected cells prior to each experiment. Geldanamycin (5 mM) purchased from Marligen Biosciences Inc. (Ijamsville, MD, USA) was used to inhibit the function of HIF.
In vitro lymphangiogenic assays HMVEC-LLy cell migration was performed in Transwells using recombinant VEGF-C at 50 ng/ml. Migrated cells were counted in 10 randomly selected high-power fields after 5 h of incubation. Lymphatic vascular tubule formation was performed in a three-dimensional culture on top of growth factorreduced Matrigel (Becton Dickinson, Bedford, MA, USA). The tubule structure was photographed 24 h after cell plating under a microscope. Vascular cross-points were counted in 10 randomly selected fields under a microscope.
Flow cytometric analysis of apoptotic populations by Annexin-V-FITC and propidium iodide staining The frequencies of apoptotic cells were determined by Annexin-V-fluorescein isothiocyanate (FITC) and propidium iodide staining. Flow cytometry was performed using a FACScalibur flow cytometer, and results were analyzed using the Cell Quest Pro software (Becton Dickinson).
Reverse transcription (RT)-PCR and real-time RT-PCR analysis
Total RNA was isolated using RNeasy Quick spin columns (Qiagen, Valencia, CA, USA). cDNA fragments of VEGF-C, VEGFR3, C/EBP-d HIF-1a and b-actin were amplified using Taq DNA polymerase.
Statistical analysis
Results are presented as the means ± s.e. for each sample. The statistical significance of differences was determined by Student's two-tailed t-test in two groups, and performed by one-way analysis of variance in multiple groups and two-factor factorial analysis of variance. All data were calculated using the Statview 5.0 (Abacus Concepts, Berkeley, CA, USA) statistical software package run on a Windows computer. The differences were considered statistically significant when P-value was o0.05.
